Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Piramal Pharma Limited operates as a pharmaceutical company in North America, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities and distribution network. It also operates contract development and manufacturing organization that provides services across the spectrum of the drug life cycle, including discovery, development, and commercial manufacturing of drug substances and products; complex hospital generics business which offers inhalation anesthetics, intrathecal therapy for spasticity management, injectable pain and anesthesia drugs, and other generic and specialty products; and India consumer healthcare business comprising analgesics, skin care, vitamin/mineral supplement, kids' wellness, digestives, women's health, and hygiene and protection. The company was incorporated in 2020 and is based in Mumbai, India.

Revenue projections:

Revenue projections for PPLPHARMA
Revenue projections for PPLPHARMA

PPLPHARMA's projected revenue decline from last year is likely to make investors cautious. Lower revenues often hurt a company's bottom line, leading investors to be concerned about the company's ability to maintain profitability and deliver strong financial results in the future.

Financial Ratios:

currentRatio 1.431000
forwardPE 48.001446
debtToEquity 60.083000
earningsGrowth 0.000000
revenueGrowth -0.088000
grossMargins 0.610460
operatingMargins -0.021600
trailingEps -0.200000
forwardEps 3.154280

Piramal Pharma Limited's current ratio is 1.431, showing the company's capacity to service its short-term debt through its cash reserves and current assets. This is a positive indicator of liquidity, suggesting Piramal Pharma Limited has no trouble covering its short-term financial obligations.
Piramal Pharma Limited's low earnings and revenue growth suggest that the company may face shrinking profits. This could indicate underlying financial challenges, making it difficult for Piramal Pharma Limited to sustain its current profitability.

Price projections:

Price projections for PPLPHARMA
Price projections for PPLPHARMA

PPLPHARMA's price projections have gradually decreased, indicating a more conservative outlook from analysts. The repeated downward revisions suggest waning confidence in the company's ability to achieve its previous targets.

Recommendation changes over time:

Recommendations trend for PPLPHARMA
Recommendations trend for PPLPHARMA


Recent analysis shows a strong buy bias for PPLPHARMA, encouraging investors to view it as a solid investment option. The positive sentiment surrounding PPLPHARMA suggests it could be an attractive place to allocate funds, motivating potential investors to consider the stock as a valuable part of their portfolio.